Search

Your search keyword '"Calvo, V"' showing total 96 results

Search Constraints

Start Over You searched for: Author "Calvo, V" Remove constraint Author: "Calvo, V" Publisher elsevier bv Remove constraint Publisher: elsevier bv
96 results on '"Calvo, V"'

Search Results

1. Advances in GeSn alloys for MIR applications

2. P1.22-16 ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

3. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

5. MA03.11 Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY

6. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

8. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

9. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial

10. EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours

11. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

12. EP13.01-016 Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital

13. EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies

16. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

17. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

18. P40.12 Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors

19. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

20. P31.02 Impact of COVID-19 Pandemic in Spanish and Portuguese Lung Cancer Patients

21. P08.01 Building Personalized Follow-Up Care Through AI by Bringing the Lung Cancer Patient, Data Scientist and Oncologist Together

24. P54.04 Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices

25. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

26. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

27. 1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer

30. FP12.01 Circulating Tumor DNA to the Identification of EGFR Positive NSCLC Long-Term Survivors

33. P09.12 SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?

34. P84.16 Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer

35. P84.14 Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.

36. P25.06 Malignant Pleural Mesothelioma: Patient Characteristics, Treatments and Outcomes from a Spanish Center

37. P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

43. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)

44. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

47. Corrections to “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis”

49. OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG

50. P1.15-24 Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients

Catalog

Books, media, physical & digital resources